Best percentage change from baseline in target lesion size. Shown for participants treated with favezelimab plus pembrolizumab in MK-4280-003 compared with resampled data from participants who received postprogression pembrolizumab in KEYNOTE-087. Resampled data are median (range) of 1000 random samples obtained from participants who received postprogression pembrolizumab in KEYNOTE-087.